Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

No studies found 3 · 42.9%GRADE not reported 0 · 0%Very low 4 · 57.1%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

End‐stage renal disease · adults and children who have IgA nephropathy proven on renal biopsy

It is very uncertain whether mizoribine regimen changes end‐stage kidney disease compared with no mizoribine regimen (very low certainty).

1 finding from 1 review

Immunosuppressive agents for treating IgA nephropathy 2020 · Cochrane Headline outcomes only
RR 1 [0.07, 14.95]
1 study · 42 participants
Very low

Complete remission · adults and children who have IgA nephropathy proven on renal biopsy

It is very uncertain whether mizoribine regimen changes complete remission compared with no mizoribine regimen (very low certainty).

1 finding from 1 review

Immunosuppressive agents for treating IgA nephropathy 2020 · Cochrane Headline outcomes only
RR 1.9 [1.06, 3.43]
1 study · 24 participants
Very low

GFR loss ≥ 50% · adults and children who have IgA nephropathy proven on renal biopsy

The review found no eligible studies for this question.

1 finding from 1 review

Immunosuppressive agents for treating IgA nephropathy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Annual GFR loss (mL/min/1.73 m2) · adults and children who have IgA nephropathy proven on renal biopsy

The review found no eligible studies for this question.

1 finding from 1 review

Immunosuppressive agents for treating IgA nephropathy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Death (any cause) · adults and children who have IgA nephropathy proven on renal biopsy

The review found no eligible studies for this question.

1 finding from 1 review

Immunosuppressive agents for treating IgA nephropathy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Infection · adults and children who have IgA nephropathy proven on renal biopsy

It is very uncertain whether mizoribine regimen changes infection compared with no mizoribine regimen (very low certainty).

1 finding from 1 review

Immunosuppressive agents for treating IgA nephropathy 2020 · Cochrane Headline outcomes only
RR 1.52 [0.14, 16.15]
2 studies · 104 participants
Very low

Malignancy · adults and children who have IgA nephropathy proven on renal biopsy

It is very uncertain whether mizoribine regimen changes malignancy compared with no mizoribine regimen (very low certainty).

1 finding from 1 review

Immunosuppressive agents for treating IgA nephropathy 2020 · Cochrane Headline outcomes only
RR 3 [0.13, 69.7]
1 study · 42 participants
Very low